Itacitinib

Drug Profile

Itacitinib

Alternative Names: INCB-039110; INCB-039110-adipate; INCB-39110; Itacitinib-adipate

Latest Information Update: 29 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Incyte Corporation
  • Developer AstraZeneca; Incyte Corporation
  • Class Antineoplastics; Antipsoriatics; Antirheumatics; Small molecules
  • Mechanism of Action Janus kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Graft-versus-host disease
  • Phase II Hodgkin's disease; Non-small cell lung cancer
  • Phase I/II Non-Hodgkin's lymphoma; Solid tumours
  • Discontinued Myelofibrosis; Pancreatic cancer; Plaque psoriasis; Rheumatoid arthritis

Most Recent Events

  • 30 Oct 2017 Incyte Corporation plans the phase I GRAVITAS-119 trial for Graft versus host disease (Combination therapy) in USA and Germany in January 2018 (NCT03320642)
  • 07 Sep 2017 Massachusetts General Hospital, Incyte Pharmaceuticals and Sundry plan a phase I trial for Malignant melanoma and Solid tumours (Combination therapy) in USA (NCT03272464)
  • 10 Aug 2017 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top